About this event
Something smells fishy: Removing doubts – Zebrafish an exceptional translational in-vivo tool for drug development and personalized medicine in cancer
Zebrafish has long been used by academic researchers to reveal molecular mechanisms involved in disease development and treatment. As a tool for cancer research, tumors transplanted to zebrafish embryos, so-called zebrafish tumor xenograft (ZTX) models, are rapidly gaining popularity. This remarkable and diverse in vivo platform has recently been revealed to have diagnostic potential by predicting patient treatment outcome and can therefore be used for precision medicine within oncology. The ZTX platform is also useful for pre-clinical drug development including lead optimization, target validation, immune-oncology, patient stratification, companion diagnostics, and so much more. In the five webinars comprising this webinar series, BioReperia will introduce the latest research based on ZTX models and their applications within drug development and personalized medicine. We will highlight the benefits and potential pitfalls of using ZTX models, and how they can synergize with other cancer model systems or diagnostic tests.
During these five consecutive months from September to January BioReperia is hosting a webinar series in five parts. Please join our webinars by registering for each individual session here, or when they are published on our LinkedIn page and website.
Webinar language: English
Part 1: 21 September 5 pm CEST
Part 2: 19 October 5 pm CEST
Part 3: 16 November 5 pm CEST
Part 4: TBA
Part 5: TBA
In this live webinar, Dr Vildevall will talk about how patient derived xenograft (PDX) models can be established in zebrafish, and how such studies have helped accelerate and de-risk late pre-clinical drug development projects. Tumor tissues from patients, implanted and expanded in immunocompromised mice, have been in used by researchers and the Pharma industry to understand how cancer drugs or disease mechanisms work before continuing to clinical trials. Such mouse PDX models are however laborious and therefore costly, and generally require a few to several months before results can be obtained. Recently, zebrafish-PDX models have been established based on bio-banked PDX-tissues and demonstrated the same response to targeted and untargeted cancer drugs as the corresponding mouse-PDX models – however with results being delivered in only 5 days.
Join this live session to find out more about how zebrafish PDX models are generated and utilized, and how they may synergize with mouse-PDX models to accelerate and de-risk late pre-clinical drug development.
Malin Vildevall, PhD
We are a contract research organization (CRO) that increase the speed for your pre-clinical drug discovery.
Share this event